BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31182680)

  • 1. Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma.
    Yang C; Liu Z; Zeng X; Wu Q; Liao X; Wang X; Han C; Yu T; Zhu G; Qin W; Peng T
    Aging (Albany NY); 2019 Jun; 11(11):3679-3703. PubMed ID: 31182680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
    Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
    Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
    Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.
    Li Q; Wang H; Zogopoulos G; Shao Q; Dong K; Lv F; Nwilati K; Gui XY; Cuggia A; Liu JL; Gao ZH
    Oncotarget; 2016 Nov; 7(47):77838-77853. PubMed ID: 27788482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
    Abe T; Koi C; Kohi S; Song KB; Tamura K; Macgregor-Das A; Kitaoka N; Chuidian M; Ford M; Dbouk M; Borges M; He J; Burkhart R; Wolfgang CL; Klein AP; Eshleman JR; Hruban RH; Canto MI; Goggins M
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1161-1169.e5. PubMed ID: 31676359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma.
    Xu C; Jun E; Okugawa Y; Toiyama Y; Borazanci E; Bolton J; Taketomi A; Kim SC; Shang D; Von Hoff D; Zhang G; Goel A
    Gastroenterology; 2024 Jan; 166(1):178-190.e16. PubMed ID: 37839499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer.
    Ben-Ami R; Wang QL; Zhang J; Supplee JG; Fahrmann JF; Lehmann-Werman R; Brais LK; Nowak J; Yuan C; Loftus M; Babic A; Irajizad E; Davidi T; Zick A; Hubert A; Neiman D; Piyanzin S; Gal-Rosenberg O; Horn A; Shemer R; Glaser B; Boos N; Jajoo K; Lee L; Clancy TE; Rubinson DA; Ng K; Chabot JA; Kastrinos F; Kluger M; Aguirre AJ; Jänne PA; Bardeesy N; Stanger B; O'Hara MH; Till J; Maitra A; Carpenter EL; Bullock AJ; Genkinger J; Hanash SM; Paweletz CP; Dor Y; Wolpin BM
    Gut; 2024 Mar; 73(4):639-648. PubMed ID: 38123998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma.
    Zhang XP; Chen Q; Liu Q; Wang Y; Wang F; Zhao ZM; Zhao GD; Lau WY; Gao YZ; Liu R
    J Cell Mol Med; 2021 Jun; 25(12):5615-5627. PubMed ID: 33942483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
    Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A protein-based prognostic model for pancreatic ductal adenocarcinoma: Construction and validation.
    Xu Y; Wang Y; Chen Q; Yao T; Qiu J; Ni L; Chen H; Liang T
    Pancreatology; 2023 Dec; 23(8):1003-1013. PubMed ID: 37923686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEACAM7 expression contributes to early events of pancreatic cancer.
    Dhasmana A; Dhasmana S; Kotnala S; Laskar P; Khan S; Haque S; Jaggi M; Yallapu MM; Chauhan SC
    J Adv Res; 2024 Jan; 55():61-72. PubMed ID: 36828119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SDC1 and ITGA2 as novel prognostic biomarkers for PDAC related to IPMN.
    Zhang CL; Shen Q; Liu FD; Yang F; Gao MQ; Jiang XC; Li Y; Zhang XY; En GE; Pan X; Pang B
    Sci Rep; 2023 Oct; 13(1):18727. PubMed ID: 37907515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing.
    Jang SI; Lee HK; Chang EJ; Kim S; Kim SY; Hong IY; Kim JK; Lee HS; Yang J; Cho JH; Lee DK
    Cancer Immunol Immunother; 2023 Aug; 72(8):2757-2768. PubMed ID: 37165046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma thymidine kinase activity as a prognostic biomarker in pancreatic ductal adenocarcinoma: a single-center prospective study.
    Asplund E; Bergqvist M; Krook M; Löhr JM
    Scand J Gastroenterol; 2023; 58(9):1044-1048. PubMed ID: 37038772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological risk based on preoperative serum CA19-9 and histological grade predicts prognosis and improves accuracy of classification in patients with pancreatic ductal adenocarcinoma.
    Chang S; Liu Y; Liang Y; Man Q; Li H; Guo Y; Zhao T
    Cancer Rep (Hoboken); 2023 Dec; 6(12):e1911. PubMed ID: 37827990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.
    Rezagholizadeh F; Tajik F; Talebi M; Taha SR; Shariat Zadeh M; Farhangnia P; Hosseini HS; Nazari A; Mollazadeh Ghomi S; Kamrani Mousavi SM; Haeri Moghaddam N; Khorramdelazad H; Joghataei MT; Safari E
    Front Immunol; 2024; 15():1283364. PubMed ID: 38357542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
    van Oosten AF; Groot VP; Dorland G; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ; Daamen LA
    Ann Surg; 2024 Mar; 279(3):493-500. PubMed ID: 37389896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.
    Xu Y; Wang Y; Höti N; Clark DJ; Chen SY; Zhang H
    Mass Spectrom Rev; 2023 Mar; 42(2):822-843. PubMed ID: 34766650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid Biopsy for Pancreatic Cancer by Serum Extracellular Vesicle-Encapsulated Long Noncoding RNA HEVEPA.
    Takahashi K; Inuzuka T; Shimizu Y; Sawamoto K; Taniue K; Ono Y; Asai F; Koyama K; Sato H; Kawabata H; Iwamoto H; Yamakita K; Kitano Y; Teramoto T; Fujiya M; Fujii S; Mizukami Y; Okumura T
    Pancreas; 2024 May; 53(5):e395-e404. PubMed ID: 38416857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges.
    Dbouk M; Abe T; Koi C; Ando Y; Saba H; Abou Diwan E; MacGregor-Das A; Blackford AL; Mocci E; Beierl K; Dbouk A; He J; Burkhart R; Lennon AM; Sokoll L; Canto MI; Eshleman JR; Goggins M
    Clin Cancer Res; 2023 Oct; 29(20):4178-4185. PubMed ID: 37566230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.